Episurf — Regulatory Filings 2016

Feb 25, 2016

Company Announcement February 25, 2016

Episurf Medical has been granted additional US patent

Episurf Medical has obtained another granted patent in the United States. The patent covers a method of manufacturing for the company's patient-specific joint implants and associated surgical tools. This is the first patent in this family of patents to be granted.

The generation of new intellectual property and the ongoing maintenance of current IP is a key activity which ensures that Episurf's proprietary, existing technologies and future innovations are well protected. The company currently has approximately 80 active patents and patent applications, distributed in 20 patent families.

For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical Tel: +46 (0) 70-7655892 Tel: +44 (0) 7803-753603 rosemary@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system will enable implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.

Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.